What is the long-term trend for NewAmsterdam Pharma Company's derivative liability, current?

Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's derivative liability, current has grown at a 139.9% compound annual growth rate (CAGR), from $4.15M to $57.27M.

NewAmsterdam Pharma Company NAMS Derivative Liability, Current

Derivative Liability, Current at other companies

Cheniere EnergyLNG

$2.55B+259%

Royal Caribbean GroupRCL

$12M-65.7%

Williams CompaniesWMB

$101M+6.3%

FAN

Diamondback EnergyFANG

$62M-17.3%

Duke EnergyDUK

$91M-59.6%

Enterprise Products PartnersEPD

$992M+84.4%

Other financials

Income statement

See full

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

See full

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

See full

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

See full

Market cap$3.67B+63.7%

Profitability

See full

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

See full

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's derivative liability, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NewAmsterdam Pharma Company's derivative liability, current?: NewAmsterdam Pharma Company (NAMS) reported derivative liability, current of $50.23M in Q1 2026.
How has NewAmsterdam Pharma Company's derivative liability, current changed year-over-year?: NewAmsterdam Pharma Company's derivative liability, current increased by 113.5% year-over-year, from $23.52M to $50.23M.
What is the long-term trend for NewAmsterdam Pharma Company's derivative liability, current?: Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's derivative liability, current has grown at a 139.9% compound annual growth rate (CAGR), from $4.15M to $57.27M.